Clinical Trial Update: Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas [Phase 2]

View source ↗

Summary

A Phase 2 pilot biomarker trial evaluated itraconazole for efficacy in basal cell carcinoma; trial completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Skin Cancer

Drugs mentioned

• Itraconazole (Itraconazole)

Snippet

Sponsor: Stanford University | Conditions: Basal Cell Carcinoma (BCC), Skin Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-11-13